Trends of lipid abnormalities among newly detected type-2 diabetes mellitus in a tertiary care hospital in Karnataka, India

Chethan T. K.; Venugopal K.

doi:10.18203/2394-6040.ijcmph20160645

Authors

Chethan T. K. Department of Community Medicine, Adichunchangiri Institute of Medical Sciences B G Nagar, Mandya, Karnataka
Venugopal K. Raghu Hospital, Sira, Tumkur Karnataka

DOI:

https://doi.org/10.18203/2394-6040.ijcmph20160645

Keywords:

Triglycerides, High density lipoproteins, Low density lipoproteins, Atherosclerosis, Type-2 diabetes mellitus

Abstract

Background: Diabetes mellitus is a common and a chronic disease with chronic complications and constitutes a substantial burden for both patient and health care system. Insulin resistance and type 2 diabetes are associated with a clustering of interrelated plasma lipid and lipoprotein abnormalities, which include reduced HDL cholesterol, a predominance of small dense LDL particles, and elevated triglyceride levels. Aims and objectives were to study the pattern of lipid abnormalities in newly detected type-2 diabetic patients.

Methods:A cross sectional study was conducted at Vijayanagara Institute of Medical Sciences Hospital and College, Bellary from May 2014 to November 2014. A total of 300 newly detected diabetic patients were included in the study. Blood Examination was done to estimate low density lipoprotein (LDL), high density lipoprotein (HDL) and triglycerides (TG).

Results: Out of 300 patients, lipid abnormality was seen in 200/300 (66.67%) of the patients. Increased LDL noted in 152 (50.67%), triglycerides in 112 (40.67%), decreased HDL in 130 (43.34%) of patients.

Conclusions:It is clearly evident that dyslipidaemia is very common association of type 2 diabetes mellitus, and culprit of majority diabetic related cardiovascular mortality.

Metrics

Metrics Loading ...

References

Whiting DR, Guariguata L, Weil C, Shaw J. IDF diabetes atlas: global estimates of the prevalence of diabetes for 2011 and 2030. Diabetes Res Clin Pract. 2011;94:311-21.

Wild S, Roglic G, Green A. Global prevalence of diabetes. Estimates for the year 2000 and projections for 2030. Diabetes care. 2004;27(5):1047-53.

Zimmer P, Alberti KG, Shaw J. Global and societal implications of the diabetes epidemic. Nature. 2001;414:782-7.

Shaw JE, Sicree RA, Zimmet PZ. Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes Res Clin Pract. 2010;87:4-14.

American Diabetes Association. Type 2 diabetes in children and adolescents. Diabetes Care. 2000;23:381-9.

Goldberg RB, Capuzzi D: Lipid disorders in type 1 and type 2 diabetes. Clin Lab Med. 2001;21:147-72.

Wingard DL, Barrett-Connor E: Heart disease and diabetes. In Diabetes in America. 2nd ed. Bethesda, MD, National Diabetes Data Group, National Institutes of Health. 1995;429-48.

Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M: Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med. 1998;339:229-34.

Ali A, Khem A, Syed. Disturbances of lipoprotein metabolism in diabetes. J Ayub Med Coll Abottabad.1999;11:3-5.

Valabhji J, Elkeles RS. Dyslipidemia in Type 2 Diabetes: Epidemiology and Biochemistry. British Journal of Diabetes and Vascular Disease. 2003;311-5.

Ronald M. Lipid and lipoproteins in type 2 diabetes.Diabetes Care. 2004;27:1496-504.

Krauss RM: Atherogenicity of triglyceride-rich lipoproteins. Am J Cardiol. 1998;81:13B-7.

McNamara JR, Jenner JL, Li Z, Wilson PW, Schaefer EJ: Change in LDL particle size is associated with change in plasma triglyceride concentration. Arterioscler Thromb Vasc Biol. 1992;12:1284-90.

Krauss RM, Williams PT, Lindgren FT, Wood PD. Coordinate changes in levels of human serum low and high density lipoprotein subclasses in healthy men. Arteriosclerosis. 1988;8:155-62.

Berneis KK, Krauss RM: Metabolic origins and clinical significance of LDL heterogeneity. J Lipid Res. 2002;43:1363-79.

Blanche PJ, Gong EL, Forte TM, Nichols AV: Characterization of human highdensity lipoproteins by gradient gel electrophoresis electrophoresis. Biochim Biophys Acta. 1981;665:408-19.

Boden G: Role of fatty acids in the pathogenesis of insulin resistance and NIDDM. Diabetes.1997;46:3-10.

Bluher M, Kratzsch J, Paschke R: Plasma levels of tumor necrosis factor, angiotensin II, growth hormone, and IGF-I are not elevated in insulin-resistant obese individuals with impaired glucose tolerance. Diabetes Care.2001;24:328-34.

Dresner A, Laurent D, Marcucci M, Griffin ME, Dufour S, Cline GW, et al: Effects of free fatty acids on glucose transport and IRS-1-associated phosphatidylinositol 3-kinase activity. J Clin Invest. 1999;103:253-9.

Reaven GM, Chen YD: Role of abnormal free fatty acid metabolism in the development of non-insulin-dependent diabetes mellitus. Am J Med. 1988;85:106-12.

Ogbera AO, Fasanmade OA, Chinenye S, Akinlade A. characterization of lipid parameters in diabetes mellitus- a Nigerian report. Int Arch Med. 2009;20;2(1):19;1795-7.

Goyal RKGU, Maheswary A. Coronary risk and dislipidemia in diabetes mellitus. J assoc physians India. 2001;49:970-3.

Lamarche B, Depres JP, Moorjani S, Cantin B, Dagenais GR, Lupien PJ: Triglycerides and HDL-cholesterol as risk factors for ischemic heart disease: results from the Quebec Cardiovascular Study. Atherosclerosis. 1996;119:235-45.

Manninen V, Tenkanen L, Koskinen P, Huttunen JK, Ma¨ntta¨ri M, Heinonen OP, et al: Joint effects of serum triglyceride and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki Heart Study: implications for treatment. Circulation. 1992;85:37-45.